About ARTBIO
ARTBIO is a company based in Sacramento (United States) founded in 2021 by Roy H Larsen and Oyvind Bruland. ARTBIO has raised $245.3 million across 3 funding rounds from investors including ARE, Third Rock Ventures and F-Prime Capital. ARTBIO offers products and services including AB001, AlphaDirect TM, and Pipeline Programs. ARTBIO operates in a competitive market with competitors including Advanced Accelerator Applications, SOFIE, AdvanCell, Ariceum Therapeutics and Mariana Oncology, among others.
- Headquarter Sacramento, United States
- Founders Roy H Larsen, Oyvind Bruland
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Artbio Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$245.3 M (USD)
in 3 rounds
-
Latest Funding Round
$132 M (USD), Series B
Jul 29, 2025
-
Investors
ARE
& 6 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of ARTBIO
ARTBIO offers a comprehensive portfolio of products and services, including AB001, AlphaDirect TM, and Pipeline Programs.
Targets prostate cancer with precise radiation treatment
Produces isotopes for advanced cancer therapies
Develops multiple therapies for various solid tumors
People of ARTBIO
Unlock access to complete
Funding Insights of ARTBIO
ARTBIO has successfully raised a total of $245.3M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $132 million completed in July 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in ARTBIO
ARTBIO has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include ARE, Third Rock Ventures and F-Prime Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital funding is provided to early-stage life science companies.
|
Locked | Locked | Locked | |
|
Investments in life sciences, technology, healthtech, and crypto sectors from global locations.
|
Locked | Locked | Locked | |
|
Venture capital firm
|
Locked | Locked | Locked |
Investor details for ARTBIO
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by ARTBIO
Investment portfolio details for ARTBIO
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - ARTBIO
Detailed financials for ARTBIO
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Artbio Comparisons
Peer comparison for ARTBIO
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of ARTBIO
ARTBIO operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Advanced Accelerator Applications, SOFIE, AdvanCell, Ariceum Therapeutics and Mariana Oncology, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| Locked | Locked | Locked |
Developer of molecular imaging systems and radio-pharmaceuticals
|
|
| Locked | Locked | Locked |
Radiopharmaceutical company developing targeted alpha therapies for cancer treatment
|
|
| Locked | Locked | Locked |
Developer of drugs for systemic targeted radiation therapy to treat cancer
|
|
| Locked | Locked | Locked |
Targeted radiopharmaceuticals for solid tumors are developed and pioneered.
|
Detailed competitors of ARTBIO
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Artbio
Complete news archive for ARTBIO
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ARTBIO
ARTBIO was founded in 2021 and raised its 1st funding round 2 years after it was founded.
ARTBIO is headquartered in Sacramento, United States. It is registered at Sacramento, California, United States.
Emanuele Ostuni is the current CEO of ARTBIO.
ARTBIO is a funded company, having raised a total of $245.3M across 3 funding rounds to date.
ARTBIO was founded in 2021 and is based in Sacramento, United States. Alpha radioligand therapies for cancer treatment are developed by the company, with lead-212 employed as the primary alpha-emitting isotope. Operations focus on targeted radioligand applications in oncology. The lead program, AB001, is directed toward prostate cancer. Co-founders include Roy H. Larsen and Oyvind Bruland, with Emanuele Ostuni serving as CEO.
ARTBIO's top competitors include Advanced Accelerator Applications, SOFIE and AdvanCell.
ARTBIO offers AB001, AlphaDirect TM, and Pipeline Programs.
ARTBIO has 7 investors. Key investors include ARE, Third Rock Ventures, F-Prime Capital, Omega Funds, and Sofinnova.